Competitor Analysis: Cancer Vaccines
Albany, NY (PRWEB) March 25, 2014
The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Browse Full Report With TOC : http://www.marketresearchreports.biz/analysis-details/competitor-analysis-cancer-vaccines
Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.
Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.
To Get Download Full Report with TOC : http://www.marketresearchreports.biz/sample/sample/139872
The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:
Target / Mechanism of Action,
Class of Compound,
R&D Stage and
additional comments with a hyperlink leading to the source of information
To Read Complete Report with TOC : http://www.marketresearchreports.biz/analysis/139872
Table of Contents
1.Cancer Vaccines by Main Composition
Peptide-based Cancer Vaccines
Protein-based Cancer Vaccines
Idiotype Antibody-based Cancer Vaccines
DNA-based Cancer Vaccines: naked and virally vectored
RNA-based Cancer Vaccines
Virus-Like Particle (VLP)-based Cancer Vaccines
Dendritic Cell-based Cancer Vaccines
Tumor Cell and Tumor Cell Line – based Cancer Vaccines
Microorganism-based Cancer Vaccines
Other and Not Defined Cancer Vaccines
2.Corporate Cancer Vaccines R&D Pipelines
Interferon Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 – 2019: http://www.marketresearchreports.biz/analysis-details/interferon-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Interferons are a class of proteins generated and released by the host cells in response to the presence of pathogenic microbes such as bacteria, viruses, fungi and tumor cells. Interferons belong to a class of glycoproteins called cytokines and are referred to as first line defenders against microbial infections. Owing to presence of the ability to ‘interfere in viral cell replication’, these proteins fight against an infection by triggering an immune response, that results in the generation of immunologic cells, such as T-cells, natural killer cells and macrophages. Usage of interferon is identified as one of the most advanced and effective clinical methods for treatment of numerous diseases such as hepatitis, sclerosis and cancer.
The market for interferon is projected to show a promising and lucrative growth in the next few years due to continued research and development activities in this field. At present, there are more than 15 human interferons available in the market and this number is expected to grow rapidly in the near future. Increasing global awareness for interferon therapy, rising demand for specialized medicines for diseases such as hepatitis-B, hepatitis-C and cancer and technological advancements in the R&D are some of the factors estimated as the major drivers for interferon market. However, patent expiration, high cost of treatment and R&D are some of the factors expected to hinder the growth of this market.
Sample Request: http://www.marketresearchreports.biz/sample/toc/191325
The global interferon market is segmented on the basis of applications of interferons, such as hepatitis-B, hepatitis C, melanoma, leukemia (interferon alpha), multiple sclerosis (interferon beta), renal cell carcinoma, leukemia (interferon gamma) and others. Moreover, the market can also be segmented on the basis of geographical regions, namely North America, Europe, Asia-Pacific and RoW. North America is identified as the key market owing to technological advancement, growing demand for sophisticated treatment of chronic diseases and strong financial ability to invest in R&D. However, Asia Pacific region is expected to show a rapid and promising growth in the upcoming year, owing to rise in awareness about interferon therapy, an increase in financial ability for R&D and others.
Some of the market players in the interferon market include Roche Inc., Merck & Co.,Inc. Biogen Inc. and others.
Enterovirus Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Enteroviruses are small, contagious single-stranded ribonucleic acid (RNA) viruses associated with several human and mammalian diseases. The enterovirus genus comprise 12 species which includes four major serotypes including poliovirus, coxsackievirus, echovirus and enterovirus. The newly identified enteroviruses are named with a system of consecutive numbers as EV68, EV69, EV70, etc. Enteroviruses are among the most common human viruses, infecting approximately one billion people annually, majorly infants and children. Diseases such as polio, meningitis, pancreatitis, hepatitis, encephalitis, hand, foot and mouth disease; birth defects, attention deficit hyperactivity disorder and cardiac disorders are caused by different types of enteroviruses.
These viruses are directly or indirectly transferred from person to person typically by the fecal-oral route, respiratory route and also from the mother to infant in the peripartum period. However, more than 50% of enterovirus infections are asymptomatic. Mild symptoms such as cold and fever occur in the infected person. Therefore, diagnosis of this infection is difficult and would be made easy with technological advancement in diagnostic tools.
Based on the type of diagnostic tests, the enterovirus diagnostic market is analyzed into viral isolation testing, serology testing and polymerase chain reaction (PCR) assay. Viral isolation method is the standard diagnostic method performed by isolating virus from the CSF, blood or feces or from multiple sites. PCR, on the other hand, is a very sensitive and specific diagnostic test method providing rapid test results. In addition, based on the site of diagnosis, the enterovirus diagnostic market is analyzed into four categories as hospitals, commercial or private laboratories, public health laboratories and physician offices. There has been rising number of private clinical laboratories which is taking away the market share of public health laboratories. Public health laboratories are usually the preferred testing sites for endemic infections.
Sample Request: http://www.marketresearchreports.biz/sample/toc/191323
Some of the growth drivers of this market include rising population, lack of vaccination in some low and middle income countries and malnutrition, deteriorating the immune system and activating the enterovirus present in the human body.
Key players in the global enterovirus diagnostic market include Merck Millipore, Quidel Corporation, Norgen Biotek Corp., Quest Diagnostics, BioMerieux, Cepheid, Thermo Fisher Scientific Inc., Alere, Inc. and Abbott Laboratories Ltd.
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Office: United States
90 State Street, Suite 700
Albany, NY 12207
Toll Free: 866-997-4948